Ensho Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ensho Therapeutics's estimated annual revenue is currently $1.6M per year.
- Ensho Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Ensho Therapeutics has 10 Employees.
Ensho Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, President, CEO and Executive Chair | Reveal Email/Phone |
2 | Chief Development Officer | Reveal Email/Phone |
3 | Chief Legal Officer & Chief Operating Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | COO and Chief Legal Officer | Reveal Email/Phone |
7 | Chief Development Officer | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Chief Data Science Officer | Reveal Email/Phone |
Ensho Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $9.1M | 59 | -9% | N/A | N/A |
#10 | $16.6M | 107 | 3% | N/A | N/A |
What Is Ensho Therapeutics?
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 10 | -37% | N/A |
#2 | $1.2M | 10 | -41% | N/A |
#3 | $0.9M | 10 | N/A | N/A |
#4 | $1.5M | 10 | N/A | N/A |
#5 | $0.9M | 10 | N/A | N/A |